Citations

Clear

16281 citation(s) found for "Yu, David".

Novel method of iliac accessory rods for rod fracture prevention in adult deformity surgery: a case series of 82 patients with outcomes and complications
Berlin, Connor , Ben‐Israel, David , Park, Brian J. , Yen, Chun-Po , Shaffrey, Mark E., Sardi, José , Ibrahim, Sufyan , Smith, Justin S.

Mayo Clinic

Journal of Neurosurgery: Spine | July 26, 2024 | Volume: 43 | Issue: 4 | Pages: 424-432

10.3171/2024.5.spine24208 | PMID 39059456 Get It

OBJECTIVE Primary rod fracture after surgery for adult spinal deformity (ASD) is a leading cause of revision, with recent prospective multicenter fracture rates reported at 11%–14% by 2 years. Consequently, the addition of supplemental rods has been explored to reduce fractures. Here the authors describe their experience with a novel iliac accessory rod technique in which each accessory rod anchors to an independent iliac bolt caudally via lateral connector, and attaches to the primary rod rostrally via side-to-side connector. METHODS This retrospective, single-center case series included patients who underwent thoracolumbar/lumbar fusion for ASD between March 2019 and August 2023. Data on baseline demographics, radiographic parameters, surgical characteristics, complications, rod fracture, and revision rates were collected. Paired, 2-tailed t-tests were used to compare pre- and postoperative radiographic outcomes. Rod fracture rates were compared to prior investigations via chi-square goodness of fit testing. The technique for iliac accessory rod placement is described. RESULTS The study consisted of 82 patients (mean age 66 years, 51% female, 26% with prior fusion) with a median follow-up of 2 years (IQR 28–104 weeks). A total of 50 patients (61%) had ≥ 2-year follow-up. Each surgery involved an average of 4 posterior column osteotomies and 8 segments. Iliac accessory rods were cobalt chromium and were placed bilaterally in 87% of constructs. Postoperative alignment improved significantly in the following parameters: maximum coronal Cobb angle, fractional curve, sagittal vertical axis, lumbar lordosis, thoracic kyphosis, and pelvic incidence to lumbar lordosis mismatch (p < 0.001 for all comparisons). Of 50 patients with ≥ 2-year follow-up, rod fracture occurred in 1 (2.0%), which was incidentally found and required no intervention. The present rod fracture rate was significantly lower than the authors’ historically reported institutional rate of 21% for traditional dual-rod constructs, and the 11%–14% reported in recent prospective multicenter studies that used traditional and supplemental rod constructs (p < 0.05 for all comparisons). Reoperation occurred in 12 patients (14.6%); 7 (8.5%) for proximal junctional kyphosis and 5 (6.1%) for wound complication. CONCLUSIONS Here the authors describe their experience with a novel iliac accessory rod technique to prevent rod fracture in patients undergoing surgery for ASD. The 2-year rod fracture rate (2.0%) in this study is significantly lower than the authors’ historical dual-rod fracture rate, and other prospective multicenter investigations. Future studies with longer follow-up are needed to determine the durability of this technique.
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non–Small Cell Lung Cancer
Ross, Helen J. , Kozono, David , Wang, Xiaofei F., Urbanic, James J., Nelson, Garth D. , Byun, Woo Yul , Talabere, Tiffany, DuFrane, Carter, Bāra, Ilze, Schulze, Katja , Brockman, Michelle, Gao, Junheng , Stinchcombe, Thomas E. , Kozono, David E , Williams, Terence M. , Carbone, David Paul , Chung, Dongjun , Robb, Ryan N. , Vokes, Everett E.

Mayo Clinic

JAMA Oncology | July 25, 2024 | Volume: 10 | Issue: 9 | Pages: 1212

10.1001/jamaoncol.2024.1897 | PMID 39052256 Get It

Importance Outcomes for patients with unresectable stage III non–small cell lung cancer (NSCLC) treated with chemoradiation therapy (CRT) have improved with adjuvant immune checkpoint inhibitors, with a reported 5-year overall survival benefit of approximately 10% for adjuvant durvalumab vs placebo after completion of CRT without progression and with preserved performance status. Starting atezolizumab prior to CRT may allow more patients to benefit from immunotherapy. Objective To evaluate clinical outcomes of patients treated with atezolizumab before and after CRT for unresectable stage III NSCLC. Design, Setting, and Participants This single-cohort, phase II, nonrandomized controlled trial was conducted at 11 US sites. Patients with pathologically confirmed, unresectable stage III NSCLC who were treatment naive and had good performance status were enrolled between January 3, 2018, and July 24, 2019. Data were locked on March 21, 2023. Interventions Patients received four 21-day cycles of atezolizumab, 1200 mg intravenously, with therapy administered on day 1 of each cycle. Patients not experiencing tumor progression continued to CRT (60 Gy to involved fields) concurrent with weekly carboplatin area under the curve of 2 and paclitaxel, 50 mg/m 2 , followed by planned consolidation carboplatin area under the curve of 6 and paclitaxel, 200 mg/m 2 , for two 21-day cycles. Patients not experiencing progression continued atezolizumab, 1200 mg, every 21 days to complete 1 year of therapy. Main Outcomes and Measures The primary end point was the disease control rate at 12 weeks. Secondary end points were progression-free survival, overall survival, overall response rate, safety, and translational science end points. Results A total of 62 patients (median [range] age, 63.9 [38.1-86.5] years; 32 female [51.6%]) were enrolled and received at least 1 dose of atezolizumab. The disease control rate at 12 weeks was 74.2% (80% CI, 65.7%-81.4%). Median progression-free survival was 30.0 months (95% CI, 15.8 to not evaluable), and the median overall survival was not reached. The overall survival rate at 24 months was 73.7% (95% CI, 63.4%-85.7%), and the overall response rate was 66.2%. Seventeen patients (27.4%) experienced grade 3 or higher immune-related adverse events, including 1 with grade 5 pneumonitis and 1 with grade 4 Guillain-Barré syndrome. Thirty patients (48.4%) experienced grade 3 or higher treatment-related adverse events. Conclusions and Relevance These findings suggest that neoadjuvant atezolizumab merits further study based on safety and encouraging outcomes. Trial Registration ClinicalTrials.gov Identifier: NCT03102242
Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study
Lampert, Rachel , Day, Sharlene M. , Ainsworth, Barbara E. , Burg, Matthew M. , Marino, Bradley S. , Salberg, Lisa , Tome, Maite , Abrams, Dominic J. , Aziz, Peter F. , Barth, Cheryl , Behr, Elijah R. , Bell, Cheyanne , Berul, Charles I. , Bos, J. Martijn , Cannom, David S. , Cannon, Bryan C. , Concannon, Maryann, Czosek, Richard J. , Dubin, Anne M. , Dziura, James , Erickson, Christopher C. , Etheridge, Susan P. , Gray, Belinda , Haglund-Turnquist, Carla , Johnsrude, Christopher L. , Lara, Alice, Saarel, Elizabeth V. , Sanatani, Shubhayan , Shah, Maully J. , Simone, Laura, Tomaselli, Gordon F., Ware, James S. , Zaręba, Wojciech , Ackerman, Michael J. , Day, Sharlene , Burg, Matthew , Tome Esteban, Maria Teresa , Bos, Johan M , Cannon, Bryan C , Cerrone, Marina , Czosek, Richard J , Dubin, Anne M , Dziura, James , Erickson, Christopher C , Estes, N.A. Mark , Etheridge, Susan P , Goldenberg, Ilan , Gray, Belinda , Haglund-Turnquist, Carla M , Harmon, Kimberly G , James, Cynthia A , Johnsrude, Christopher , Kannankeril, Prince J , Law, Ian H , Link, Mark S. , Molossi, Silvana M , Olshansky, Brian , Noseworthy, Peter A , Saarel, Elizabeth V , Sanatani, Shubhayan , Shah, Maully , Skinner, Jonathan R , Ware, James S , Webster, Gregory , Zareba, Wojciech , Zipes, Douglas P , Ackerman, Michael J , Behr, Elijah Raphael , Abrams, Dominic J , Bradley, David J. , Cerrone, Marina , Goldenberg, Ilan , Harmon, Kimberly G. , James, Cynthia A. , Kannankeril, Prince J. , Law, Ian H. , Li, Fangyong , Olshansky, Brian , Noseworthy, Peter A. , Skinner, Jonathan R. , Webster, Gregory , Zipes, Douglas P.

Mayo Clinic

Circulation | July 25, 2024 | Volume: 150 | Issue: 7 | Pages: 516-530

10.1161/circulationaha.123.067590 | PMID 39051104 Get It

BACKGROUND: Whether vigorous exercise increases risk of ventricular arrhythmias for individuals diagnosed and treated for congenital long QT syndrome (LQTS) remains unknown. METHODS: The National Institutes of Health–funded LIVE-LQTS study (Lifestyle and Exercise in the Long QT Syndrome) prospectively enrolled individuals 8 to 60 years of age with phenotypic and/or genotypic LQTS from 37 sites in 5 countries from May 2015 to February 2019. Participants (or parents) answered physical activity and clinical events surveys every 6 months for 3 years with follow-up completed in February 2022. Vigorous exercise was defined as ≥6 metabolic equivalents for >60 hours per year. A blinded Clinical Events Committee adjudicated the composite end point of sudden death, sudden cardiac arrest, ventricular arrhythmia treated by an implantable cardioverter defibrillator, and likely arrhythmic syncope. A National Death Index search ascertained vital status for those with incomplete follow-up. A noninferiority hypothesis (boundary of 1.5) between vigorous exercisers and others was tested with multivariable Cox regression analysis. RESULTS: Among the 1413 participants (13% <18 years of age, 35% 18–25 years of age, 67% female, 25% with implantable cardioverter defibrillators, 90% genotype positive, 49% with LQT1, 91% were treated with beta-blockers, left cardiac sympathetic denervation, and/or implantable cardioverter defibrillator), 52% participated in vigorous exercise (55% of these competitively). Thirty-seven individuals experienced the composite end point (including one sudden cardiac arrest and one sudden death in the nonvigorous group, one sudden cardiac arrest in the vigorous group) with overall event rates at 3 years of 2.6% in the vigorous and 2.7% in the nonvigorous exercise groups. The unadjusted hazard ratio for experience of events for the vigorous group compared with the nonvigorous group was 0.97 (90% CI, 0.57–1.67), with an adjusted hazard ratio of 1.17 (90% CI, 0.67–2.04). The upper 95% one-sided confidence level extended beyond the 1.5 boundary. Neither vigorous or nonvigorous exercise was found to be superior in any group or subgroup. CONCLUSIONS: Among individuals diagnosed with phenotypic and/or genotypic LQTS who were risk assessed and treated in experienced centers, LQTS-associated cardiac event rates were low and similar between those exercising vigorously and those not exercising vigorously. Consistent with the low event rate, CIs are wide, and noninferiority was not demonstrated. These data further inform shared decision-making discussions between patient and physician about exercise and competitive sports participation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02549664.
Blending diverse expertise to optimise and sustain project outcomes
Kamath, Janine R., Barclay, Jason E., Baude, Lydia A., Ehman, Jeffrey R., Williams, Bradley E., Khan, Munawwar A., Hanf, Nicole K., O’Brien, David M.

Mayo Clinic

Management in Healthcare: A Peer-Reviewed Journal | July 25, 2024 | Volume: 5 | Issue: 1 | Pages: 15

10.69554/xzzw2024 Get It

Strategic projects in large healthcare organisations are often highly complex and dynamic, and they require a team of skilled business professionals to execute them. Examples of difficult, costly and extended project executions have been shared in the literature. Successful project execution involves many critical facets. One facet that continues to be of marked interest is effective resourcing of strategic projects. This paper focuses on describing a staffing approach used at Mayo Clinic (Rochester, Minnesota) to facilitate successful, agile and sustainable execution, with desired outcomes. In 2016, Management Engineering & Consulting (ME&C) began exploring a collaborative staffing model that partnered management engineers with project managers (PMs) to drive strategic, multisite projects. This ongoing collaboration model was evaluated from multiple perspectives, including project outcomes, timeliness, client and staff satisfaction and opportunities for innovation. Data and feedback on the model were collected with historical reports, surveys and focus groups with stakeholders, leaders, PMs and management engineers. The feedback and data indicated that the collaborative staffing strategy and model have further optimised service delivery, enabled professional staff to work at the highest level of their competency and dynamically blended knowledge, expertise and skills to achieve better and more sustainable overall project outcomes.
Incorporating health systems engineering into COVID-19 vaccine planning and administration
Casadonte, Tarin A., Dhanorker, Atul S., Elsen, Sandra J., Krishnan, Nalini P., Lohmann, Shane A., Lu, Luqing, Macickova, Jana, Martindale-Mathern, Sonia C., Ring, David A., Stearly, Joseph R., Ring, David A.

Mayo Clinic

Management in Healthcare: A Peer-Reviewed Journal | July 25, 2024 | Volume: 6 | Issue: 1 | Pages: 6

10.69554/gmed2370 Get It

The COVID-19 pandemic has created unique logistical challenges for vaccine transportation, inventory management, allocation and distribution at multiple levels — the federal government, states and healthcare institutions. Unpredictable weekly vaccine allocation from state health departments, changing population priorities, stringent vaccine requirements for ultracold storage, transportation, reconstitution and 2-dose administration intervals have presented challenges never seen before in the history of mass vaccination programmes, including those at Mayo Clinic. To meet the challenges, an efficient system of allocation and administration for COVID-19 vaccines was developed through collaboration with process engineering. To understand the challenges, ten health systems engineers from the Department of Management Engineering & Consulting at Mayo Clinic facilitated the institution-wide COVID-19 vaccine project, collaborating closely with diverse multidisciplinary teams that included physicians, nurses, pharmacists, administrative services, information technology, human resources, scheduling operations and public affairs. The internal consultants designed tools and solutions based on systems and process engineering methodologies to solve a myriad of complex problems, including identifying priority populations, using resources efficiently and minimising vaccine waste. Tools designed included a vaccine resource playbook; dynamic staffing models based on vaccine allocation, storage, inventory and distribution processes using a hub-andspoke model; workflows and staffing models for face-to-face and drive-through vaccine administration sites; and end-of-day workflows to reduce vaccine waste. Through the collaboration, modelling and engineering, multiple sites across Mayo Clinic have implemented successful COVID-19 vaccination programmes that are efficient in resource utilisation and have minimal waste. In this paper, we share what we have learned to help other healthcare organisations prepare for future mass vaccination scenarios.
Eosinophilic esophagitis and other non-reflux esophageal disorders
Katzka, David A.

Mayo Clinic

The Biomedical & Life Sciences Collection | July 25, 2024 | Volume: 2011 | Issue: 1 | Pages: e1002813

10.69645/wxwm5663 Get It

Hsp90: a chaperone for protein kinases and hormone receptors
Toft, David O.

Mayo Clinic

The Biomedical & Life Sciences Collection | July 25, 2024 | Volume: 2007 | Issue: 10 | Pages: e1001681

10.69645/kres2435 Get It

Standardizing Retrospective Observational Research in Cutaneous Squamous Cell Carcinoma
Cheraghlou, Shayan , Christensen, Sean R. , Walker, Joanna, Ferrándiz‐Pulido, Carla , Bibee, Kristin , Carter, Joi B., Samie, Faramarz H. , Carroll, Bryan T. , Vidimos, Allison T. , Baum, Christian L. , Leitenberger, Justin J. , Jambusaria‐Pahlajani, Anokhi , Ruiz, Emily S. , Carr, David R. , Shahwan, Kathryn T. , Stevenson, Mary L. , Bordeaux, Jeremy S. , Srivastava, Divya , Patel, Vishal Anil , Carucci, John A. , Carr, David R.

Mayo Clinic

JAMA Dermatology | July 24, 2024 | Volume: 160 | Issue: 9 | Pages: 989

10.1001/jamadermatol.2024.2242 | PMID 39046711 Get It

ImportanceCutaneous squamous cell carcinoma (CSCC) is the second most common malignant disease in the US. Although it typically carries a good prognosis, a subset of CSCCs are highly aggressive, carrying regional and distant metastatic potential. Due to its high incidence, this aggressive subset is responsible for considerable mortality, with an overall annual mortality estimated to equal or even surpass melanoma. Despite this morbidity, CSCC is excluded from national cancer registries, making it difficult to study its epidemiology and outcomes. Therefore, the bulk of the CSCC literature is composed of single-center and multi-institutional retrospective cohort analyses. Given variations in reporting measures and analyses in these studies, interpretability between studies and the ability to pool results are limited.ObjectiveTo define standardized reporting measures for retrospective CSCC studies.FindingsAn expert panel was convened to determine standardized guidelines for recording and analyzing retrospective CSCC data. A total of 13 dermatologists and dermatologic surgeons with more than 5 years of posttraining experience and considerable experience with performing CSCC outcomes research were recruited to the panel. Consensus recommendations were achieved for CSCC retrospective study reporting measures, definitions, and analyses.Conclusions and RelevanceThe recommendations in this report present the potential to standardize future CSCC retrospective studies. With such standardization, future work may have greater interstudy interpretability and allow for pooled analyses.
Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer’s disease
Josephs, Keith A. , Tosakulwong, Nirubol , Weigand, Stephen D. , Graff-Radford, Jonathan, Schwarz, Christopher G. , Senjem, Matthew L. , Machulda, Mary M. , Kantarci, Kejal , Knopman, David S. , Nguyen, Aivi T. , Reichard, R. Ross , Petersen, Ronald C. , Lowe, Val J. , Jack, Clifford R. , Whitwell, Jennifer L., Knopman, David S. , Nguyen, Aivi T , Dickson, Dennis W , Petersen, Ronald C , Jack, Clifford R , Schwarz, Christopher G , Senjem, Matthew L , Kantarci, Kejal , Machulda, Mary M , Graff‐Radford, Jonathan , Dickson, Dennis W. , Whitwell, Jennifer

Mayo Clinic

Science Translational Medicine | July 24, 2024 | Volume: 16 | Issue: 757 | Pages: No page available

10.1126/scitranslmed.ado8076 | PMID 39047115 Get It

[ 18 F]-Flortaucipir positron emission tomography (PET) is considered a good biomarker of Alzheimer’s disease. However, it is unknown how flortaucipir is associated with the distribution of tau across brain regions and how these associations are influenced by amyloid-β. It is also unclear whether flortaucipir can detect tau in definite primary age–related tauopathy (PART). We identified 248 individuals at Mayo Clinic who had undergone [ 18 F]-flortaucipir PET during life, had died, and had undergone an autopsy, 239 cases of which also had amyloid-β PET. We assessed nonlinear relationships between flortaucipir uptake in nine medial temporal and cortical regions, Braak tau stage, and Thal amyloid-β phase using generalized additive models. We found that flortaucipir uptake was greater with increasing tau stage in all regions. Increased uptake at low tau stages in medial temporal regions was only observed in cases with a high amyloid-β phase. Flortaucipir uptake linearly increased with the amyloid-β phase in medial temporal and cortical regions. The highest flortaucipir uptake occurred with high Alzheimer’s disease neuropathologic change (ADNC) scores, followed by low-intermediate ADNC scores, then PART, with the entorhinal cortex providing the best differentiation between groups. Flortaucipir PET had limited ability to detect PART, and imaging-defined PART did not correspond with pathologically defined PART. In summary, spatial patterns of flortaucipir mirrored the histopathological tau distribution, were influenced by the amyloid-β phase, and were useful for distinguishing different ADNC scores and PART.
Guidelines for management of actual or suspected inadvertent intra-arterial injection of sclerosants
Parsi, Kurosh , Maeseneer, Marianne De , Rij, André M. van , Bonython, Wendy , Devereux, John , Lekich, C, Amos, Michael, Bozkurt, Ahmet Kursat , Connor, David , Gianesini, Sergio , Gibson, Kathleen , Grabs, Anthony J., Grillo, Lorena, Hafner, Franz, Iafrati, Mark D. , Jackson, Mark , Jindal, Ravul , Raymond-Martimbeau, Pauline, Paraskevas, P, Ramelet, Albert‐Adrien , Roberts, Stefania , Simkin, Carlos, Thibault, P , Whiteley, Mark S , Lim, Adrian , De Maeseneer, Marianne , Bozkurt, Ahmet Kursat , Connor, David E , Davies, Alun H , Gianesini, Sergio , Gibson, Kathleen , Raymond-Martimbeau, Pauline , Thibault, Paul K , Whiteley, Mark S , Parsi, Kurosh , Rogan, Christopher , Davies, Alun H. , Gloviczki, Péter , Huber, David, Lim, Adrian, Lurie, Fedor , Marks, Lisa, Rial, Rodrigo

Mayo Clinic

Phlebology: The Journal of Venous Disease | July 24, 2024 | Volume: 39 | Issue: 10 | Pages: 683-719

10.1177/02683555241260926 | PMID 39046331 Get It

Background Inadvertent intra-arterial injection of sclerosants is an uncommon adverse event of both ultrasound-guided and direct vision sclerotherapy. This complication can result in significant tissue or limb loss and significant long-term morbidity. Objectives To provide recommendations for diagnosis and immediate management of an unintentional intra-arterial injection of sclerosing agents. Methods An international and multidisciplinary expert panel representing the endorsing societies and relevant specialities reviewed the published biomedical, scientific and legal literature and developed the consensus-based recommendations. Results Actual and suspected cases of an intra-arterial sclerosant injection should be immediately transferred to a facility with a vascular/interventional unit. Digital Subtraction Angiography (DSA) is the key investigation to confirm the diagnosis and help select the appropriate intra-arterial therapy for tissue ischaemia. Emergency endovascular intervention will be required to manage the risk of major limb ischaemia. This includes intra-arterial administration of vasodilators to reduce vasospasm, and anticoagulants and thrombolytic agents to mitigate thrombosis. Mechanical thrombectomy, other endovascular interventions and even open surgery may be required. Lumbar sympathetic block may be considered but has a high risk of bleeding. Systemic anti-inflammatory agents, anticoagulants, and platelet inhibitors and modifiers would complement the intra-arterial endovascular procedures. For risk of minor ischaemia, systemic oral anti-inflammatory agents, anticoagulants, vasodilators and antiplatelet treatments are recommended. Conclusion Inadvertent intra-arterial injection is an adverse event of both ultrasound-guided and direct vision sclerotherapy. Medical practitioners performing sclerotherapy must ensure completion of a course of formal training (specialty or subspecialty training, or equivalent recognition) in the management of venous and lymphatic disorders (phlebology), and be personally proficient in the use of duplex ultrasound in vascular (both arterial and venous) applications, to diagnose and provide image guidance to venous procedure. Expertise in diagnosis and immediate management of an intra-arterial injection is essential for all practitioners performing sclerotherapy.